| Identification | Back Directory | [Name]
2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- | [CAS]
1262857-73-7 | [Synonyms]
NB-360
CHS360
Inhibitor,BACE,NB 360,β-Secretase,inhibit,NB-360,NB360,Beta-secretase
2-Pyridinecarboxamide, N-[3-[(3R,6R)-5-amino-3,6-dihydro-3,6-dimethyl-6-(trifluoromethyl)-2H-1,4-oxazin-3-yl]-4-fluorophenyl]-5-cyano-3-methyl- | [Molecular Formula]
C21H19F4N5O2 | [MDL Number]
MFCD32215319 | [MOL File]
1262857-73-7.mol | [Molecular Weight]
449.4 |
| Hazard Information | Back Directory | [Uses]
NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E[1][2]. | [storage]
Store at -20°C | [References]
[1] Neumann U, et al. Mol Neurodegener. 2015 Sep 3;10:44. doi: 10.1186/s13024-015-0033-8. DOI:10.1186/s13024-015-0033-8
[2] Neumann U, et al. The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects. Br J Pharmacol. 2019 Sep;176(18):3435-3446. DOI:10.1111/bph.14582 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|